表紙
市場調査レポート

デジタルPCR技術レポート:ベンダー、コストおよびエンドユーザーコミュニティの分析

Digital PCR Technology Report: An Insight to Vendors, Costs & the End User Community

発行 Insight Pharma Reports 商品コード 273161
出版日 ページ情報 英文 106 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.39円で換算しております。
Back to Top
デジタルPCR技術レポート:ベンダー、コストおよびエンドユーザーコミュニティの分析 Digital PCR Technology Report: An Insight to Vendors, Costs & the End User Community
出版日: 2013年05月29日 ページ情報: 英文 106 Pages
概要

デジタルPCRはリアルタイムPCRよりも高い感度・特異度が可能な研究開発における新しいアプローチです。このことは、珍しい遺伝子変異、コピー数変異、ウィルス、胎児異常やその他多くのことについての研究者による綿密な調査を可能にします。いくつかの国立計量標準研究所も、デジタルPCRを参考基準として検討すると同時に、診断ラボ向け参考基準を作成するためにその精密さ・正確さを利用しています

当レポートでは、デジタルPCR技術について調査し、デジタルPCR装置の供給ベンダー、機器の評価、および研究におけるデジタルPCRの影響の分析を提供しており、概略下記の構成で取り上げております。

主な調査内容

エンドユーザーコミュニティのフィードバック

  • 使いやすさ
  • サンプル調製
  • リアルタイムPCRアッセイとの統合
  • 改良領域
  • 顧客満足度

220人以上の参加者による詳細調査の結果

主要ベンダーへのインタビュー

  • RainDance Technologies
  • Bio-Rad Laboratories
  • Life Technologies
  • Fluidigm Corporation

国立計量標準研究所へのインタビュー

  • National Institute of Standards and Technology (NIST) :米国立標準技術研究所
  • LGC Group
  • National Measurement Institute (NMI) Australia:オーストラリア全国計測協会

デジタルPCR装置の仕様比較表:以下の項目を含む

  • プラットフォーム種類
  • サンプルあたりの反応数
  • 実行もしくは分析可能な装置のサンプル数
  • 検出タイプ(エンドポイントもしくはリアルタイム)
  • 反応量
  • 製品あたりのコスト
  • 実行あたりのコスト
  • サンプルあたりのコスト
  • 1万反応あたりのコスト

利用可能なプラットフォームの詳細な説明

目次

Available Now!

Newly Released Report, with expanded focus, coverage and primary data!

The newly released Insight Pharma Report is about the digital PCR technologies that have surfaced in the market. Digital PCR is a new application in research and development allowing for higher sensitivity and specificity than real-time PCR. This allows researchers to closely examine rare genetic mutations (including single nucleotide polymorphisms), copy number variations, viruses, prenatal defects, and much more. National measurement institutions have also been looking into digital PCR as a reference standard as well as using its precision and accuracy to create reference standards for diagnostic labs.

This report focuses on the main vendors supplying digital PCR systems, validation of the instruments, and digital PCR's impact in research. By detecting rare sequences that were previously undetected with real-time PCR, digital PCR has enabled scientists to accelerate their research. However, there are many areas of the new technology that have been overlooked and neglected, and this report covers those aspects as well.

Also included in this report are:

  • Feedback from end-user communities
    • Ease of use
    • Sample preparation
    • Integration with real-time PCR assays
    • Areas of improvement
    • Customer satisfaction
  • In-depth survey results from over 220 participants. Results are depicted over 12 charts and graphs and contain responses from Academia/Universities, Biotechnology companies, Pharmaceutical companies, Government/Clinical organizations, and Other technology providers, covering information on their familiarity of digital PCR and vendors, as well as expected future use.
  • Interviews with the main vendors in the market space including
    • RainDance Technologies
    • Bio-Rad Laboratories
    • Life Technologies
    • Fluidigm Corporation
  • Interviews with national measurement institutions including
    • National Institute of Standards and Technology (NIST)
    • LGC Group
    • National Measurement Institute (NMI) Australia
  • Six tables including a comparison table with specifications of the digital PCR instruments including
    • Type of platform
    • Number of reactions per sample
    • Number of samples the instruments can run or analyze
    • Type of detection (end-point or real-time)
    • Reaction volume
    • Total volume
    • Cost per products
    • Cost per run
    • Cost per sample
    • Cost per 10,000 reactions
  • Detailed descriptions of the platforms available

Table of Contents

Executive Summary

Chapter 1: What is Digital PCR?

  • 1.1. Introduction
  • 1.2. Background Information
  • 1.3. Digital PCR Platforms

Chapter 2: Sensitivity of Digital PCR

  • 2.1. Analyzing Preserved Samples
  • 2.2. Ability to Detect Copy Number Variations (CNVs) and Single Nucleotide Polymorphisms (SNPs)
  • 2.3. Integration with Real-time PCR Assays

Chapter 3: Areas of Improvement for Digital PCR

  • 3.1. Higher Throughput
  • 3.2. Multiplexing
  • 3.3. Recovering Samples
  • 3.4. Cost

Chapter 4: Digital PCR Instruments

Chapter 5: RainDance Technologies

  • 5.1. Background
  • 5.2. RainDrop Digital PCR System
  • 5.3. What is the Process of the RainDrop Digital PCR System?
  • 5.4. Areas of Improvement and Customer Feedback
  • 5.5. Interview With Andy Watson, Chief Commercial Officer at RainDance Technologies
    • 5.5.1. Background
    • 5.5.2. RainDrop Digital PCR System
    • 5.5.3. Sample Preparation and Analysis
    • 5.4.4. Customer Feedback
    • 5.5.5. Future of Digital PCR
    • 5.5.6. Competitive Advantage

Chapter 6: Bio-Rad Laboratories

  • 6.1. Background Information
  • 6.2. QX100 Droplet Digital PCR System
  • 6.3. What is the Process of the QX100 Droplet Digital PCR System?
  • 6.4. Areas of Improvement and Customer Feedback
  • 6.5. Interview With Annette Tumolo, Vice President and General Manager of the Digital Biology Center at Bio-Rad Laboratories
    • 6.5.1. Background
    • 6.5.2. QX100 Dropelet Digital PCR System
    • 6.5.3. Sample Preparation and Analysis
    • 6.5.4. Customer Feedback
    • 6.5.5. Future of Digital PCR
    • 6.5.6. Competitive Advantage

Chapter 7: Life Technologies

  • 7.1. Background
  • 7.2. QuantStudio 3D Digital PCR System
  • 7.3. What is the Process of the QuantStudio 3D Digital PCR System?
  • 7.4. Areas of Improvement and Customer Feedback
  • 7.5. Interview With Mauricio Minotta, Sr. Manager of Corporate Communications at Life Technologies
    • 7.5.1. Background
  • 7.6. Interview With Paco Cifuentes, Director of the Product Application for the Genetic Analysis Business at Life Technologies
    • 7.6.1. QuantStudio 3D Digital PCR System
    • 7.6.2. Sample Preparation and Analysis
    • 7.6.3. Customer Feedback
    • 7.6.4. Future of Digital PCR
    • 7.6.5. Competitive Advantage

Chapter 8: Fluidigm Corporation

  • 8.1. Background
  • 8.2. BioMark HD System vs. EP1 System
  • 8.3. 12.765 Digital Array vs. qdPCR 37K IFC
  • 8.4. How do all the Components Work Together?
  • 8.5. What is the Process of the of BioMark HD System?
    • 8.5.1. BioMark HD System
    • 8.5.2. EP1 System
  • 8.6. Areas of Improvement and Customer Feedback
  • 8.7. Interview With Howard High, Senior Fellow, Corporate Communications and Press Officer at Fluidigm Corporation
    • 8.7.1. Background
    • 8.7.2. Digital PCR Systems (BioMark HD and EP1)
    • 8.7.3. Digital PCR Chips (12.765 Digital Array IFC and qdPCR 37K IFC)
    • 8.7.4. Sample Preparation and Analysis
    • 8.7.5. Customer Feedback
    • 8.7.6. Future of Digital PCR
    • 8.7.7. Competitive Advantage

Chapter 9: Comparison of Instrument Specifications

Chapter 10: Design Comparisons

Chapter 11: Digital PCR Use in National Measurement Institutions

Chapter 12: National Institute of Standards and Technology (NIST), United States

  • 12.1. Background
  • 12.2. Poisson Statistics
  • 12.3. Digital PCR Use
  • 12.4. Feedback and Areas of Improvement
  • 12.5. Conclusion
  • 12.6. Interview With Ross Haynes, Technician of Biological Science at National Institute of Standards and Technology (NIST), USA
    • 12.6.1. Background
    • 12.6.2. Poisson Statistics
    • 12.6.3. Digital PCR in NIST Research
    • 12.6.4. Digital PCR Platforms
    • 12.6.5. Digital PCR as a Reference Standard
    • 12.6.6. Digital PCR Pros and Cons

Chapter 13: LGC Group, United Kingdom

  • 13.1. Background
  • 13.2. Advantages
  • 13.3. Precision vs. Accuracy
  • 13.4. Validation of Digital Technology
  • 13.5. Estimation of Molecules
  • 13.6. Sample Collection, Preparation, and Storage
  • 13.7. Inter-Laboratory Comparability
  • 13.8. Feedback and Areas of Improvement
  • 13.9. Conclusion
  • 13.10. Interview With Jim Huggett, Science Leader in Nucleic Acid Metrology at LGC Group, UK
    • 13.10.1. Background
    • 13.10.2. Digital PCR Use
    • 13.10.3. Sample Preparation
    • 13.10.4. Validation
    • 13.10.5. Results
    • 13.10.6. Feedback and Areas of Improvement

Chapter 14: National Measurement Institute (NMI) Australia

  • 14.1. Background
  • 14.2. Reference Standard
  • 14.3. Validation
  • 14.4. Feedback and Areas of Improvement
  • 14.5. Conclusion
  • 14.6. Interview With Kerry Emslie, Manager of the Bioanalysis Group at National Institute of Measurement (NMI) Australia
    • 14.6.1. Background
    • 14.6.2. Digital PCR Application
    • 14.6.3. Validation
    • 14.6.4. Sample Preparation and Analysis
    • 14.6.5. Feedback and Areas of Improvement
    • 14.6.6. Future Outlook

Chapter 15: Digital PCR Use in Research and Development

  • 15.1. Organizations Surveyed
  • 15.2. How well is Digital PCR Known?
  • 15.3. Digital PCR Use in Future Research
  • 15.4. Conclusion
  • 15.5. Survey Questions

References

Acronyms Used In This Report

About Cambridge Healthtech Institute

Back to Top